DelveInsight, a leading healthcare market research and consulting firm, has released its latest report, “Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036.” The report provides a comprehensive understanding of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia epidemiology, market size, market trends, treatment landscape, emerging therapies, market share, and forecast across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market
The Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market size across the 7MM is anticipated to grow significantly during the forecast period 2022–2036.
The United States accounted for the largest Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market share among the 7MM in 2025 and is expected to maintain its dominance throughout the forecast period.
DelveInsight estimates indicate that the total HABP/VABP market size in the 7MM is expected to increase from approximately USD 613 million in 2022 to nearly USD 2.2 billion by 2036.
Ventilator-associated pneumonia remains the second most common nosocomial infection and is a leading cause of mortality among critically ill hospitalized patients.
Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are primarily caused by pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, and Acinetobacter baumannii.
According to DelveInsight estimates, incident cases of HABP/VABP are expected to increase across the 7MM during the forecast period, driven by increasing ICU admissions, aging populations, and antimicrobial resistance trends.
Leading Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia companies such as BioVersys, Venatorx Pharmaceuticals, Merck, AbbVie, and others are actively developing innovative treatment options to address resistant pathogens.
Promising Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia therapies in development include BV-100 and Cefepime-Taniborbactam, among others.
Keen to know more about the market? Request our sample page at:https://www.delveinsight.com/sample-request/hospital-acquired-and-ventilator-associated-bacterial-pneumonia-market
Key Factors Driving the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market
Rising Burden of Multidrug-Resistant Pathogens
The increasing prevalence of multidrug-resistant Gram-negative organisms, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacterales, continues to create substantial demand for advanced antibacterial therapies. The growing threat of antimicrobial resistance is a major factor supporting Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market growth.
Increasing ICU Admissions and Mechanical Ventilation Usage
The growing number of critically ill patients requiring prolonged hospitalization, intensive care unit admission, and mechanical ventilation significantly contributes to the incidence of HABP/VABP. This trend is expected to support continued expansion of the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia treatment market.
Advancements in Novel Antibiotic Development
Growing investments in antibacterial drug development and increasing regulatory support for innovative anti-infective therapies are accelerating the emergence of new treatment options. Novel agents targeting resistant pathogens are expected to improve treatment outcomes and strengthen the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia drug market.
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Competitive Landscape
The Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market currently includes approved therapies such as ZERBAXA (ceftolozane/tazobactam) from Merck and AVYCAZ (ceftazidime/avibactam) from AbbVie. These therapies have demonstrated effectiveness against multidrug-resistant Gram-negative pathogens and remain key components of the treatment landscape.
The emerging Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia pipeline remains relatively limited but includes promising candidates such as BV-100 (BioVersys) and Cefepime-Taniborbactam (Venatorx Pharmaceuticals). These therapies are designed to address unmet needs associated with resistant bacterial infections and may significantly influence future market dynamics.
Discover more about therapies set to grab major Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia market share @ Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Treatment Landscape
Recent Developments in the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market
In December 2025, BioVersys initiated Phase III clinical trials evaluating BV-100 for ventilator-associated bacterial pneumonia, with pivotal data anticipated in the second half of 2027.
In October 2024, BioVersys announced completion of the last patient visit in its Phase II clinical study evaluating BV-100 for serious hospital-acquired infections caused by carbapenem-resistant Acinetobacter baumannii.
Cefepime-Taniborbactam continues Phase III clinical development for HABP/VABP and complicated urinary tract infections.
In November 2023, Venatorx Pharmaceuticals entered an exclusive licensing agreement with Melinta Therapeutics for commercialization of Cefepime-Taniborbactam in the United States.
What is Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia?
Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) are serious nosocomial infections that develop in hospitalized patients, particularly those receiving mechanical ventilation. HABP occurs 48 hours or more after hospital admission, while VABP develops after at least 48 hours of endotracheal intubation and mechanical ventilation. These infections are associated with significant morbidity, mortality, prolonged hospital stays, increased healthcare costs, and growing antimicrobial resistance challenges.
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Epidemiology Segmentation
The Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:
Total Incident Cases of Bacterial Pneumonia
Total Incident Cases of HABP/VABP
Etiology-specific Cases of HABP/VABP
Total Treated Cases of HABP/VABP
Scope of the Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Report
Therapeutic Assessment: Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia marketed and emerging therapies
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Dynamics: Market drivers, barriers, opportunities, and future trends
Key Companies: BioVersys, Venatorx Pharmaceuticals, Merck, AbbVie, and others
Key Therapies: BV-100, Cefepime-Taniborbactam, ZERBAXA, AVYCAZ, and others
Competitive Intelligence Analysis: SWOT analysis, market positioning, and competitive benchmarking
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Size, Market Share, Treatment Trends, and Forecast
KOL Views, Analyst Perspectives, Market Access, and Reimbursement Analysis
To know more about Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia companies working in the treatment market, visit @ Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Clinical Trials and Therapeutic Assessment
Table of Contents
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Report Introduction
Executive Summary of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
SWOT Analysis of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Overview at a Glance
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Epidemiology and Patient Population
Country-Specific Epidemiology Analysis
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Current Treatment Practices
Patient Journey Analysis
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Unmet Needs
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Emerging Therapies
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Outlook
Country-Wise Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Analysis (2022–2036)
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Access and Reimbursement
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Drivers
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers actionable market intelligence, epidemiology forecasts, competitive landscape assessments, pipeline analysis, and strategic consulting services through its subscription-based healthcare intelligence platform, PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
